Q-Cells is under clinical development by Q Therapeutics and currently in Phase II for Transverse Myelitis (TM). According to GlobalData, Phase II drugs for Transverse Myelitis (TM) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Q-Cells LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Q-Cells overview
Q-Cells is under development for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease), multiple sclerosis, stroke, spinal cord injury and demyelinating diseases such as transverse myelitis. The therapy is administered through parenteral route as an injection which consist of is human glial-restricted progenitor (GRP) cells.
Q Therapeutics overview
Q Therapeutics, Inc.(Q Therapeutics) develops cell-based therapeutics. The Company focuses on developing novel products to treat amyotrophic lateral sclerosis, cerebral palsy, stroke, traumatic brain injury, and alzheimer’s disease.It is headquartered in Salt Lake City, Utah, the US.
For a complete picture of Q-Cells’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
